Pfizer: Ulcerative Colitis Competitive Grant Program

Pfizer has issued an RFP for its Ulcerative Colitis Competitive Grant Program.

Through the program, grants of up to $150,000 (clinical) and up to $75,000 (translational) research will be awarded in support of research on the pathogenesis and treatment of ulcerative colitis (UC), with a specific focus on projects that are especially to improving patient care.

Specific areas of interest include:

Clinical Research — Improving UC management through treat-to-target strategies or innovative symptom monitoring (e.g., studies investigating the use of technology); and understanding predictors of response to tofacitinib and utility of biomarkers in the management of UC.

Translational Research — Understanding the role of JAK-STAT signaling in the pathophysiology or disease progression of IBD. Studies exploring the relationship between JAK-STAT and either platelet or endothelial biology and its impact on VTE risk; the application of proteomic, transcriptomic, and genomic techniques to predict disease progression or treatment response in IBD; and a multi-omics understanding of the microbiome in IBD will be considered.

To be eligible, the institution and principal investigator (PI) must be based in the U.S. and the applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in pharmacy, physiotherapy, or social work.

See the Pfizer website for complete program guidelines and application instructions.